Monographie - Topotecan - Stabilis 4.0

Viimane versioon :
08/05/2024

Vähiravimite

Topotecan

Süsteravim

Stabiilsus lahustes

Stabiilsust mõjutavad tegurid

Stabiilsust mõjutavad faktorid

Sobimatus

Manustamis viis

Viited

Pdf

Keemiline struktuur

Kaubanduslikud nimed erinevates maades

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Acumil	Mehhiko
Camtoop	Mehhiko
Cantop	India
Hycamtin	Ameerika ühendriigid, Araabia Ühendemiraadid, Austraalia, Austria, Belgia, Brasiilia, Ecuador, Egiptus, Hispaania, Holland, Iirimaa, Island, Itaalia, Jaapan, Kanada, Kolumbia, Kreeka, Luksemburg, Malaisia, Norra, Poola, Portugal, Prantsusmaa, Rootsi, Saksamaa, Saudi Araabia, Soome, Suurbritannia, Sveits, Taani, Tšiili, Türgi, Ungari, Venetsueela
Oncotecan	Ecuador, Kolumbia
Potactasol	Argentiina, Belgia, Norra, Rumeenia, Saksamaa
Tekan L	Türgi
Topodria	Kolumbia
Topokebir	Argentiina, Maroko
Toposec	Maroko
Topotecan	Belgia, Hispaania, Kanada, Kolumbia, Maroko, Norra, Rumeenia, Saksamaa, Suurbritannia
Topotel	Egiptus
Toranex	Mehhiko
Tpopoxin	Türgi
Viatopin	Ungari

Viited

Süsteravim

Viited : Topotecan

	Tüüp	Avaldamine
753	Labor	Topotecan (Topotecan Hospira®) - Summary of Product Characteristics Hospira 2016
823	Ajaleht	Patel K, Craig SB, McBride MG, Palepu NR. Microbial inhibitory properties and stability of topotecan hydrochloride injection. Am J Health-Syst Pharm 1998 ; 55: 1584-1587.
1026	Ajaleht	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1075	Ajaleht	Craig SB, Bhatt UH, Patel K. Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers. J Pharm Biomed Anal 1997 ; 16: 199-205.
1274	Ajaleht	Krämer I, Thiesen J. Pharmazeutische aspekte von topotecan-infusionen. TAP Pharmazeutische Zeitung 1997 ; 31: 30-33.
1423	Ajaleht	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1425	Ajaleht	Krämer I, Thiesen J. Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices. J Oncol Pharm Practice 1999 ; 5: 75-82.
1662	Ajaleht	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1953	Ajaleht	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976	Ajaleht	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.

Mentions Légales